Estradiol treatment in a large cohort of younger women with congenital hypogonadism: how much is enough?

Abstract

17beta-Estradiol (E2 ) is a critical contributor to women's bone-, cardiovascular-, sexual- and general health during normal reproductive life, and young women with hypogonadism (YWH) therefore require hormone replacement therapy (HRT) to mitigate symptoms, protect against adverse long-term health outcomes and maintain quality of life. This article is protected by copyright. All rights reserved.